1. Clinical & Scientific Overview
Etoposide (VP-16) (TIP-MED-000564, Reference Code [ONC-15]) is classified under
Oncology & Antineoplastic Medicines as a Topoisomerase II Inhibitor (Late S / G2 Phase) • Semisynthetic Epipodophyllotoxin Topoisomerase II Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Vepesid Reference, Etosid (Cipla Ltd), Fytop (Fresenius Kabi Oncology)
Solution for IV Infusion: 100 mg/5 mL vial; Soft Gelatin Oral Capsule: 50 mg
Oncology Specialisation & Cytotoxic Safety Protocol
Topoisomerase II Inhibitor (Late S / G2 Phase)
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: 100 mg/m2/day IV over 30–60 minutes on Days 1–3 or Days 1–5 of a 21-day cycle (Oral dose is 2x IV dose due to ~50% bioavailability).
Signature Dose-Limiting Toxicities & Organ Monitoring: Rapid IV infusion (<30 minutes) causes severe Polysorbate-80/hypotensive reaction; concentration >0.4 mg/mL precipitates in IV bag; dose-limiting leukopenia (nadir Day 10–14) and secondary AML involving 11q23 (KMT2A/MLL) translocation.
Extravasation, Premedication & Safe Cytotoxic Handling: Dilute in 0.9% NaCl or D5W to a final concentration strictly <=0.4 mg/mL (0.2 mg/mL preferred) to prevent precipitation in the IV bag, and infuse slowly over at least 30 to 60 minutes.
3. Mechanism of Action & Pharmacodynamics
Forms a ternary complex with DNA and Topoisomerase II alpha, preventing re-ligation of cleaved DNA strands and inducing double-stranded DNA breaks.
4. Therapeutic Indications & Evidence-Supported Uses
- Small Cell Lung Cancer (Cisplatin/Carboplatin + Etoposide)
- Testicular Germ Cell Tumours (BEP regimen)
- Hodgkin/Non-Hodgkin Lymphoma and Haemophagocytic Lymphohistiocytosis (HLH)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 100 mg/m2/day IV over 30–60 minutes on Days 1–3 or Days 1–5 of a 21-day cycle (Oral dose is 2x IV dose due to ~50% bioavailability).
Administration & Meal Timing: 100 mg/m2/day IV over 30–60 minutes on Days 1–3 or Days 1–5 of a 21-day cycle (Oral dose is 2x IV dose due to ~50% bioavailability).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Etoposide or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Rapid IV infusion (<30 minutes) causes severe Polysorbate-80/hypotensive reaction; concentration >0.4 mg/mL precipitates in IV bag; dose-limiting leukopenia (nadir Day 10–14) and secondary AML involving 11q23 (KMT2A/MLL) translocation.
8. Adverse Effects Profile
- Rapid IV infusion (<30 minutes) causes severe Polysorbate-80/hypotensive reaction; concentration >0.4 mg/mL precipitates in IV bag; dose-limiting leukopenia (nadir Day 10–14) and secondary AML involving 11q23 (KMT2A/MLL) translocation.
- Rapid IV infusion (<30 minutes) causes severe Polysorbate-80/hypotensive reaction; concentration >0.4 mg/mL precipitates in IV bag; dose-limiting leukopenia (nadir Day 10–14) and secondary AML involving 11q23 (KMT2A/MLL) translocation.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Rapid IV infusion (<30 minutes) causes severe Polysorbate-80/hypotensive reaction; concentration >0.4 mg/mL precipitates in IV bag; dose-limiting leukopenia (nadir Day 10–14) and secondary AML involving 11q23 (KMT2A/MLL) translocation.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Dilute in 0.9% NaCl or D5W to a final concentration strictly <=0.4 mg/mL (0.2 mg/mL preferred) to prevent precipitation in the IV bag, and infuse slowly over at least 30 to 60 minutes.
Pharmacist Patient Counselling Points:
- Dilute in 0.9% NaCl or D5W to a final concentration strictly <=0.4 mg/mL (0.2 mg/mL preferred) to prevent precipitation in the IV bag, and infuse slowly over at least 30 to 60 minutes.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Dilute in 0.9% NaCl or D5W to a final concentration strictly <=0.4 mg/mL (0.2 mg/mL preferred) to prevent precipitation in the IV bag, and infuse slowly over at least 30 to 60 minutes.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-14] Vincristine Sulfate — Vinca Alkaloid (M-Phase Specific) • Vinca Alkaloid Microtubule Po
- [ONC-16] Irinotecan Hydrochloride — Topoisomerase I Inhibitor (S-Phase Specific) • Water-Soluble Camp
- [ONC-17] Anastrozole — Hormonal Oncology Therapy (Aromatase Inhibitor) • Third-Generatio
- [ONC-18] Fulvestrant — Hormonal Oncology Therapy (Pure ER Antagonist/Degrader) • Selecti
